Evidence map›Paper›PMID 42018138›Full record

ArticleJACC. Basic to translational science2026

CXCL10 Regulates Pressure Overload-Induced Heart Failure.

Fernando Souza-Neto, Preston Le, Mobeen Abdrabbo, Ashab Alamgir, Haiguang Wang, Natalia Ferreira de Araujo, Jennifer L Mikkila, Bruno Sanches, Preethy Parthiban, Ryan Moon and 7 more

Abstract read
In one paragraph

Article in JACC. Basic to translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Fernando Souza-NetoLillehei Heart Institute, Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, USA.
Preston LeCollege of Science and Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
Mobeen AbdrabboDepartment of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Ashab AlamgirLillehei Heart Institute, Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, USA.
Haiguang WangDepartment of Integrative Biology & Physiology, University of Minnesota, Minneapolis, Minnesota, USA.
Natalia Ferreira de AraujoLillehei Heart Institute, Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, USA.
Jennifer L MikkilaLillehei Heart Institute, Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, USA; Department of Integrative Biology & Physiology, University of Minnesota, Minneapolis, Minnesota, USA.
Bruno SanchesDepartment of Physiology and Biophysics, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Preethy ParthibanDepartment of Integrative Biology & Physiology, University of Minnesota, Minneapolis, Minnesota, USA.
Ryan MoonLillehei Heart Institute, Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, USA.
Adam HermanDepartment of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Andrew B AdamsDepartment of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Kurt W PrinsLillehei Heart Institute, Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, USA; Gazes Cardiac Research Institute, Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Silvia GuatimosimDepartment of Physiology and Biophysics, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Nathan SchuldtDivision of Pediatric Rheumatology, Allergy and Immunology, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA; Center for Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
Xavier S ReveloDepartment of Integrative Biology & Physiology, University of Minnesota, Minneapolis, Minnesota, USA; Center for Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
Jop H van BerloLillehei Heart Institute, Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address: jvanberl@umn.edu.

Funding

TRAINING PROGRAM IN MUSCLE RESEARCHT32AR007612 · NIAMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI JAMES M ERVASTI, DAWN A LOWE · 2001 to 2026
$11.3M
Immune Mechanisms Regulating Cardiac RemodelingR01HL155993 · NHLBI · UNIVERSITY OF MINNESOTA · PI REVELO, XAVIER, VAN BERLO, JOHANNES (JOP) · 2021 to 2024
$2.9M
NHLBI NIH HHS R01 HL155993NIAMS NIH HHS T32 AR007612
6 · The paper itself

Abstract

Heart failure is a syndrome where immune cells play a crucial role in its development and progression. Although the recruitment of T cells driven by C-X-C motif chemokine receptor 3 activation has been reported, the specific contribution of C-X-C motif chemokine ligand 10 (CXCL10), one of its ligands, remains unclear. Here, we investigate the role of CXCL10 in pressure overload-induced cardiac remodeling, both in the early phase of remodeling and during heart failure progression. We used the transverse aortic constriction model to induce pressure overload in mice and assessed the role of CXCL10 in cardiac remodeling. Our study shows that the genetic deletion of CXCL10 attenuates early cardiac remodeling and with more pronounced effects 6 weeks after transverse aortic constriction, as CXCL10-/- mice exhibit reduced hypertrophy and fibrosis and are protected from the development of cardiac dysfunction, which was observed in wild-type animals. Notably, CXCL10-/- mice do not show T-cell expansion and activation in the draining lymph nodes, particularly in the CD4+ T-cell subset. Using bone marrow chimeras, we show that CXCL10 from recruited macrophages accelerates pathologic cardiac remodeling. Our findings establish CXCL10 as a key mediator of heart failure, acting through immune cell recruitment and activation. These results suggest that targeting CXCL10 could provide a novel therapeutic strategy to mitigate inflammation-driven heart failure progression.

Indexed as

cardiac dysfunctioncardiac remodelingfibrosishypertrophyinflammationmacrophagesT cells

Identifiers

PMID42018138
PMCPMC13031030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.